Literature DB >> 32697170

Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.

Adam J Gordon1,2,3, Karen Drexler4, Eric J Hawkins5,6,7, Jennifer Burden4, Nodira K Codell1, Amy Mhatre-Owens1, Matthew T Dungan1, Hildi Hagedorn8,9.   

Abstract

The US is confronted with a rise in opioid use disorder (OUD), opioid misuse, and opioid-associated harms. Medication treatment for opioid use disorder (MOUD)-including methadone, buprenorphine and naltrexone-is the gold standard treatment for OUD. MOUD reduces illicit opioid use, mortality, criminal activity, healthcare costs, and high-risk behaviors. The Veterans Health Administration (VHA) has invested in several national initiatives to encourage access to MOUD treatment. Despite these efforts, by 2017, just over a third of all Veterans diagnosed with OUD received MOUD. VHA OUD specialty care is often concentrated in major hospitals throughout the nation and access to this care can be difficult due to geography or patient choice. Recognizing the urgent need to improve access to MOUD care, in the Spring of 2018, the VHA initiated the Stepped Care for Opioid Use Disorder, Train the Trainer (SCOUTT) Initiative to facilitate access to MOUD in VHA non-SUD care settings. The SCOUTT Initiative's primary goal is to increase MOUD prescribing in VHA primary care, mental health, and pain clinics by training providers working in those settings on how to provide MOUD and to facilitate implementation by providing an ongoing learning collaborative. Thirteen healthcare providers from each of the 18 VHA regional networks across the VHA were invited to implement the SCOUTT Initiative within one facility in each network. We describe the goals and initial activities of the SCOUTT Initiative leading up to a two-day national SCOUTT Initiative conference attended by 246 participants from all 18 regional networks in the VHA. We also discuss subsequent implementation facilitation and evaluation plans for the SCOUTT Initiative. The VHA SCOUTT Initiative could be a model strategy to implement MOUD within large, diverse health care systems.

Entities:  

Keywords:  Veterans; Veterans Health Administration; buprenorphine; implementation science; opioid use disorder; stepped care

Year:  2020        PMID: 32697170     DOI: 10.1080/08897077.2020.1787299

Source DB:  PubMed          Journal:  Subst Abus        ISSN: 0889-7077            Impact factor:   3.716


  22 in total

1.  A Facility-Wide Plan to Increase Access to Medication for Opioid Use Disorder in Primary Care and General Mental Health Settings.

Authors:  Juliette F Spelman; Ellen L Edens; Susan Maya; Brent A Moore; Angela Boggs; Robert R MacLean; Princess Ackland; William C Becker; Donna Lynch; Maria Garcia-Vassallo; Andrea L Burgo; Marc I Rosen; Adam J Gordon
Journal:  Fed Pract       Date:  2021-10

2.  Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder Among Patients With and Without HIV.

Authors:  Jessica J Wyse; Kathleen A McGinnis; E Jennifer Edelman; Adam J Gordon; Ajay Manhapra; David A Fiellin; Brent A Moore; P Todd Korthuis; Amy J Kennedy; Benjamin J Oldfield; Julie R Gaither; Kirsha S Gordon; Melissa Skanderson; Declan T Barry; Kendall Bryant; Stephen Crystal; Amy C Justice; Kevin L Kraemer
Journal:  AIDS Behav       Date:  2021-09-08

3.  Response to coronavirus 2019 in Veterans Health Administration facilities participating in an implementation initiative to enhance access to medication for opioid use disorder.

Authors:  Allison M Gustavson; Adam J Gordon; Marie E Kenny; Haley McHenry; Julie Gronek; Princess E Ackland; Hildi J Hagedorn
Journal:  Subst Abus       Date:  2020-09-16       Impact factor: 3.716

Review 4.  Toward a Typology of Office-based Buprenorphine Treatment Laws: Themes From a Review of State Laws.

Authors:  Barbara Andraka-Christou; Adam J Gordon; Kathryn Bouskill; Rosanna Smart; Olivia Randall-Kosich; Matthew Golan; Rachel Totaram; Bradley D Stein
Journal:  J Addict Med       Date:  2022 Mar-Apr 01       Impact factor: 3.702

5.  Aims, development, and early results of an interdisciplinary primary care initiative to address patient vulnerabilities.

Authors:  Nodira Codell; A Taylor Kelley; Audrey L Jones; Matthew T Dungan; Natalie Valentino; Ana I Holtey; Tania J Knight; Amy Butz; Christina Gallop; Sean Erickson; Jeremy Patton; Laura Jane Hyte-Richins; Benjamin Z Rollins; Adam J Gordon
Journal:  Am J Drug Alcohol Abuse       Date:  2020-12-10       Impact factor: 3.829

6.  High prevalence of unmet healthcare need among people who use illicit drugs in a Canadian setting with publicly-funded interdisciplinary primary care clinics.

Authors:  Soroush Moallef; Fahmida Homayra; M-J Milloy; Lorna Bird; Bohdan Nosyk; Kanna Hayashi
Journal:  Subst Abus       Date:  2020-12-03       Impact factor: 3.716

7.  Buprenorphine prescriber monthly patient caseloads: An examination of 6-year trajectories.

Authors:  Irineo Cabreros; Beth Ann Griffin; Brendan Saloner; Adam J Gordon; Rose Kerber; Bradley D Stein
Journal:  Drug Alcohol Depend       Date:  2021-09-22       Impact factor: 4.492

8.  Strategies to improve implementation of medications for opioid use disorder reported by veterans involved in the legal system: A qualitative study.

Authors:  Erica Morse; Ingrid A Binswanger; Emmeline Taylor; Caroline Gray; Matthew Stimmel; Christine Timko; Alex H S Harris; David Smelson; Andrea K Finlay
Journal:  J Subst Abuse Treat       Date:  2021-03-04

9.  Impact of intensity of behavioral treatment, with or without medication treatment, for opioid use disorder on HIV outcomes in persons with HIV.

Authors:  Amy J Kennedy; Kathleen A McGinnis; Jessica S Merlin; E Jennifer Edelman; Adam J Gordon; P Todd Korthuis; Melissa Skanderson; Emily C Williams; Jessica Wyse; Benjamin Oldfield; Kendall Bryant; Amy Justice; David A Fiellin; Kevin L Kraemer
Journal:  J Subst Abuse Treat       Date:  2021-05-29

10.  It will end in tiers: A strategy to include "dabblers" in the buprenorphine workforce after the X-waiver.

Authors:  Brendan Saloner; Barbara Andraka Christou; Adam J Gordon; Bradley D Stein
Journal:  Subst Abus       Date:  2021-04-02       Impact factor: 3.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.